Abstract:ConspectusCells, particularly living cells, serve as natural carriers of bioactive substances. Their inherent low immunogenicity and multifunctionality have garnered significant attention in the realm of disease treatment applications, specifically within the domains of cancer immunotherapy and regenerative tissue repair. Nevertheless, several prominent challenges impede their swift translation into clinical applications, including obstacles related to large-scale production feasibility and high utilization costs. To address these issues comprehensively, researchers have proposed the notion of bionic cells that are synthetically generated through chemical or biosynthetic means to emulate cellular functions and behaviors. However, artificial cell strategies encounter difficulties in fully replicating the intricate functionalities exhibited by living cells while also grappling with the complexities associated with design implementation for clinical translation purposes. The convergence of disciplines has facilitated the reform of living cells through a range of approaches, including chemical-, biological-, genetic-, and materials-based methods. These techniques can be employed to impart specific functions to cells or enhance the efficacy of therapy. For example, cells are engineered through gene transduction, surface modifications, endocytosis of drugs as delivery systems, and membrane fusion. The concept of engineered cells presents a promising avenue for enhancing control over living cells, thereby enhancing therapeutic efficacy while concurrently mitigating toxic side effects and ultimately facilitating the realization of precision medicine.In this Account, we present a comprehensive overview of our recent research advancements in the field of engineered cells. Our work involves the application of biological or chemical engineering techniques to manipulate endogenous cells for therapeutics or drug delivery purposes. For instance, to avoid the laborious process of isolating, modifying, and expanding engineered cells in vitro, we proposed the concept of in situ engineered cells. By applying a hydrogel loaded with nanoparticles carrying edited chimeric antigen receptor (CAR) plasmids within the postoperative cavity of glioma, we successfully targeted tumor-associated macrophages for gene editing, leading to effective tumor recurrence inhibition. Furthermore, leveraging platelet's ability to release microparticles upon activation at injury sites, we modified antiprogrammed death 1 (PD-1) antibodies on their surface to suppress postoperative tumor recurrence and provide immunotherapy for inoperable tumors. Similarly, by exploiting bacteria's active tropism toward sites of inflammation and hypoxia, we delivered protein drugs by engineered bacteria to induce cancer cell death through pyroptosis initiation and immunotherapy strategies. In the final section, we summarize our aforementioned research progress while providing an outlook on cancer therapy and the hurdles for clinical translation with potential solutions or future directions based on the concept of engineered cells.

Cell surface engineering and application in cell delivery to heart diseases

Metabolic Glycoengineering: A Promising Strategy to Remodel Microenvironments for Regenerative Therapy

The Recent Advances in Cell Delivery Approaches, Biochemical and Engineering Procedures of Cell Therapy Applied to Coronary Heart Disease

Advances on Non-Genetic Cell Membrane Engineering for Biomedical Applications

Leveraging Engineering of Cells for Drug Delivery

Biomaterials for Cell-Surface Engineering and Their Efficacy

Surface Engineering of Cardiovascular Devices for Improved Hemocompatibility and Rapid Endothelialization

Recent Advances on Surface-modified Biomaterials Promoting Selective Adhesion and Directional Migration of Cells

Cell-membrane engineering strategies for clinic-guided design of nanomedicine

Surface Modification Strategies for Biomedical Applications: Enhancing Cell–Biomaterial Interfaces and Biochip Performances

Bioengineering Technologies for Cardiac Regenerative Medicine

Biomedical Applications of Cell Membrane‐Based Biomimetic Nano‐Delivery System

Smart surface-based cell sheet engineering for regenerative medicine

Injectable Cardiac Tissue Engineering for the Treatment of Myocardial Infarction

Recent Advances of Cell Surface Modification Based on Aptamers

Engineering Cells for Cancer Therapy

Advancing Cell Surface Modification in Mammalian Cells with Synthetic Molecules

Surface Modification and Endothelialization of Biomaterials As Potential Scaffolds for Vascular Tissue Engineering Applications

Biomaterials‐based Cell Therapy for Myocardial Tissue Regeneration

Engineering Cell Surfaces with Polyelectrolyte Materials for Translational Applications

Cell-Based Bio-Hybrid Delivery System for Disease Treatments